Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

$1,736 $2,539

Receivables 2,096 2,026

Inventories 2,536 2,334

Other current assets 645 656

--------------------------------

Total current assets 7,013 7,555

--------------------------------

Property, plant and equipment, net 4,633 4,487

Other long-term assets 3,326 3,252

-------------------------------------------------------------------------

Total assets $14,972 $15,294

=========================================================================

Liabilities and Shareholders' Equity

------------------------------------

Short-term debt $141 $425

Other current liabilities 3,095 3,387

Long-term debt 2,731 2,664

Other long-term liabilities 2,008 1,902

Shareholders' equity 6,997 6,916

-------------------------------------------------------------------------

Total liabilities and shareholders'

equity $14,972 $15,294

=========================================================================

BAXTER INTERNATIONAL INC.

Cash Flows from Operations and Changes in Net Debt

(unaudited)

($ in millions)

Cash Flows from Operations

(Brackets denote cash outflows)


'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... three Department of Energy (DOE) bio-energy research centers, has ... valuable intellectual property. , ... ... Surety, LLC , the leading provider of ... Joint BioEnergy Institute (JBEI), one of three Department of ...
(Date:12/15/2009)... SAN DIEGO, Dec. 15 Aethlon Medical, ... that Dr. Jeff Schorey and Dr. Wayne Comper ... of Exosome Sciences, Inc. (ESI). Both Dr. Schorey ... exosome field. ESI, a wholly owned subsidiary of ... discovery that the Hemopurifier®, a medical device being ...
(Date:12/15/2009)... BRIARCLIFF MANOR, N.Y., Dec. 15 The ... announced that the professional society is continuing to ... is being held in Arlington, VA, April 19-21, ... society is encouraging non-members to join the organization ... event. The submission deadline is 12 AM EST, ...
(Date:12/15/2009)... - 45 Patients Enrolled ... Cells to Restore Cardiac Function ,, ... company specialising,in cell-based therapies for the treatment of ... months ahead of schedule,enrolment in the first stage ... a,unique stem cell therapy for heart failure. Forty-five ...
Breaking Biology Technology:Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3
... Inc. (Nasdaq:, BLUD ), a global leader in ... announced that it expects to release its,fiscal second quarter ... regular trading hours, and then host a conference call ... review the results. Investors are invited to,participate in ...
... Enhance Precision Farming Technology Available to Industry and Pioneer Customers ... ... 29, 2008 -- DuPont business Pioneer Hi-Bred and MapShots ... , a privately owned agricultural data management company that develops and ...
... and PHILADELPHIA, Pennsylvania,December 29 Rosetta Genomics, ... molecular diagnostics, announced,today the introduction of its ... now commercially available through Rosetta Genomics CLIA-certified,lab ... To order the test, physicians may contact ...
Other Biology Technology:Immucor Schedules Second Quarter Earnings Release and Conference Call 2DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers 2DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5
(Date:12/15/2009)... Clinical Laboratory, San Diego, California, has been awarded ... (CAP), based on results of a recent onsite ... advised of this national recognition and congratulated for ... Biotech Inc. GenWay Clinical Laboratory is one of ... Laboratory Accreditation Program, begun in the early 1960s, ...
(Date:12/15/2009)... a team of Spanish and American researchers found the fossil ... Huelva. Now they have published, for the first time, the ... the death of the young cetacean, possibly a baleen whale ... discovery of the partial fossil remains of a whale from ... Sands sedimentary formation, but it is the first time that ...
(Date:12/15/2009)... mouse is a standard laboratory model organism, but ... techniques to analyze blood and blood-forming tissues in ... compact and easy-to-use laboratory resources from Cold Spring ... Mouse Hematology features step-by-step protocols for the ... bone marrow, and other hematopoietic tissues in the ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3New source of classical techniques for blood-based studies in the laboratory mouse 2MarketsandMarkets 3A Global Biomarker Market Worth US 24 20 5 Billion by 2014 55808 1MarketsandMarkets 3A Global Biomarker Market Worth US 24 20 5 Billion by 2014 55808 2MarketsandMarkets 3A Global Biomarker Market Worth US 24 20 5 Billion by 2014 55808 3China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 1China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 2China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 3China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 4China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 5China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 6China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 7China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 8China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 9China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 10China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 11China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 12China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 13China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 14China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 15China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 16China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 17China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 18China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 19China Medical Technologies Reports FY2008 Fourth Fiscal Quarter and Full Year Unaudited Financial Results 55806 20MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 1MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 3MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 4
... combination of extended wakefulness and low-dose alcohol has significant ... elevates the risk of getting into a vehicular accident, ... issue of the journal SLEEP. , The study, authored ... Breathing and Sleep in Heidelberg, Victoria, Australia, focused on ...
... population, farm income, and crop production in the ... and the environment are counterbalanced by surprising stability ... , The survey, published in the October ... such as improved crop varieties, irrigation, and fertilizer ...
... carbohydrates claims that eating so-called bad carbohydrates will make ... says, thats just nonsense. Eating sandwiches with white bread, ... or necessarily even lead to obesity, he said. , ... Journal of the American Dietetic Association, Gaesser analyzes peer-reviewed, ...
Other Biology News:Extended wakefulness, combined with alcohol, severely impairs driving performance 2'Bad carbs' not the enemy, University of Virginia professor finds 2